HealthEquity: This Financial Powerhouse Is Poised To Compound Wealth (Upgrade)

Gen AlphaInvesting GroupFollow5ShareSavePlay(8min)CommentsSummaryHealthEquity is upgraded from 'Hold' to 'Buy,' reflecting visible operating leverage and durable growth drivers.HQY's fiscal Q4 2026 saw 7% revenue growth, 500+ bps margin expansion, and 23% adjusted EBITDA growth, signaling an earnings inflection.Structural tailwinds include expanded HSA eligibility, rising engagement, and a shift toward higher-value, compounding accounts.At a forward P/E of 18.1 versus a historical 53.1, HQY offers compelling value with double-digit return potential.Looking for a portfolio of ideas like this one? Members of iREIT®+HOYA Capital get exclusive access to our subscriber-only portfolios. Learn More » BrianAJackson/iStock via Getty Images It’s been a while since I last covered HealthEquity (HQY) in December 2020. I had a "Hold" rating on the stock at the time due primarily to valuation, and that appears to have been a prescient call. Since then, HQYThis article was written byGen Alpha23.2K FollowersFollowI am Gen Alpha. I have more than 14 years of investment experience, and an MBA in Finance. I focus on stocks that are more defensive in nature, with a medium- to long-term horizon. I provide high-yield, dividend growth investment ideas in the investing group iREIT®+HOYA Capital. The group helps investors achieve dependable monthly income, portfolio diversification, and inflation hedging. It provides investment research on REITs, ETFs, closed-end funds, preferreds, and dividend champions across asset classes. It offers income-focused portfolios targeting dividend yields up to 10%. Learn more.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in HQY over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I am not an investment advisor. This article is for informational purposes and does not constitute financial advice. Readers are encouraged and expected to perform due diligence and draw their own conclusions prior to making any investment decisions.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.